OXB.L - Oxford BioMedica plc
| Previous close | 539.00 |
| Open | 543.90 |
| Bid | 531.00 x 0 |
| Ask | 542.00 x 0 |
| Day's range | 513.00 - 554.16 |
| 52-week range | 356.73 - 793.00 |
| Volume | 40,011 |
| Avg. volume | 122,622 |
| Market cap | 410.573M |
| Beta (5Y monthly) | -0.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -11.60 |
| Earnings date | 23 Apr 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1,085.99 |
- Stockopedia
Will Oxford Biomedica's (LON:OXB) share price suffer because of its poor F-Score?
It's hard to keep tabs on hundreds of companies, but that's what we have to do if we want to find overlooked investment opportunities. Sometimes there just isn8230;
- Simply Wall St.
Did Oxford BioMedica plc (LON:OXB) Insiders Buy Up More Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
- Simply Wall St.
Is Oxford BioMedica's (LON:OXB) Share Price Gain Of 224% Well Earned?
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
- Simply Wall St.
We're Hopeful That Oxford BioMedica (LON:OXB) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Stockopedia
Will Oxford Biomedica's share price (LON:OXB) suffer because of its poor F-Score?
Healthcare operator Oxford Biomedica (LON:OXB) is a gene and cell therapy company that is engaged in lentiviral vector and cell therapy research, development a8230;
- Simply Wall St.
What Should We Expect From Oxford BioMedica plc's (LON:OXB) Earnings Over The Next Year?
Since Oxford BioMedica plc (LON:OXB) released its earnings in December 2018, the consensus outlook from analysts...
- Simply Wall St.
Is There An Opportunity With Oxford BioMedica plc's (LON:OXB) 23% Undervaluation?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Oxford BioMedica plc...
- EQS Group
Hardman & Co Research: Oxford BioMedica (OXB): Eying up long-term value
Hardman & Co Research 01-Jul-2019 / 11:03 GMT/BST * * *Hardman & Co: Eying up long-term valueOxford BioMedica (OXB) is a specialist, advanced therapy, viral-vector biopharma company. It offers vector manufacturing and development services, while developing proprietary drug candidates, with its LentiVector(R) platform. 2018 saw significant growth in gross income, the majority through licensing deals. A new R&D collaboration deal with Santen, coupled with the recent equity financing and debt repayment, demonstrate OXB's deal-making ability and its strategy to secure future, long-term potential. Near term, this R&D arrangement will provide modest additional profit, adding confidence to OXB's new net cash status in 2019.Please click here for the full report:https://www.hardmanandco.com/research/corporate-research/eying-up-long-term-value/To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH www.hardmanandco.com Follow us on Twitter @HardmanandCo Contacts: Dr Martin Hall Dr Dorothea Hill Dr Gregoire Pave +44 20 7194 7622 mh@hardmanandco.com dmh@hardmanandco.com gp@hardmanandco.com Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer. * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service
- Simply Wall St.
Is Oxford BioMedica plc's (LON:OXB) CEO Paid At A Competitive Rate?
John Dawson has been the CEO of Oxford BioMedica plc (LON:OXB) since 2008. This report will, first, examine the CEO...
- Simply Wall St.
Oxford BioMedica plc (LON:OXB) Delivered A Better ROE Than Its Industry
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! While some investors are already well versed in financial metrics (hat tip), this article is for thos...
- EQS Group
Hardman & Co Research: Oxford BioMedica (OXB): Deal-making drives first annual profit
Hardman & Co Research 02-Apr-2019 / 07:15 GMT/BST * * *Hardman & Co: Deal-making drives first annual profitOXB is a specialist, advanced therapy, viral-vector biopharmaceutical company. It offers vector manufacturing and development services, while developing proprietary drug candidates. OXB also receives royalties on commercial products developed with its LentiVector(R) platform. 2018 delivered significant growth in gross income, primarily through licensing income from new partnership deals with Axovant Sciences (AXON) and Bioverativ (BIVV). Licensing income was of a magnitude that delivered OXB's first full-year underlying operating profit, despite weaker-than-anticipated bioprocessing/commercial sales and investment to increase capacity.https://www.hardmanandco.com/research/corporate-research/deal-making-drives-first-annual-profit/To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH www.hardmanandco.com Follow us on Twitter @HardmanandCo Contacts: Dr Martin Hall Dr Dorothea Hill Dr Gregoire Pave +44 20 7194 7622 mh@hardmanandco.com dmh@hardmanandco.com gp@hardmanandco.com Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer. * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service
